The HER-2-VLP vaccine was then re-engineered for human administration (referred to as ES2B-C001) by ExpreS2ion Biotechnologies (Hørsholm, Denmark) and showed promising results in HER-2-positive mammary carcinoma prevention and therapy in mice. The gene discussed is ERBB2; the disease is breast carcinoma.